



Manuscripts

by SAKK and
Cooperative Groups
2024

Cancer	Trial	Title	Authors	Journal	Impact factor
Breast Cancers	IBCSG 22-00	Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00	Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammeler R, Hornfeld J, Munzone E, Gianni L, Thürlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalajt L, Coukos G, Curigliano G	EUR J CANCER	7.6
	IBCSG 24-02	Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT Trial	O'Regan RM, Zhang Y, Fleming GF, Francis PA, Kammeler R, Viale G, Dell'Orto P, Láng I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, MüllerB, Jochum W, Zaman K, Martino S, Geyer CE Jr, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM	JAMA ONCOL	22.3
	IBCSG 36-07	Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer	de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A	ESMO OPEN	7.1
	IBCSG 48-14 POSITIVE	Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy	Azim HA, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Eon Lee J, Walshe JM, Ruiz-Borrego M, Moore HC, Saunders C, Bjelic-Radicic V, Susnjar S, Cardoso F, Klar NJ, Tanja Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Peccatori FA	J CLIN ONCOL	42.1
	IBCSG 50-14 OLYMPIA	Patient-reported outcomes in OlympiA: A phase III, randomized, placebo-controlled trial of adjuvant olaparib in g BRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer	Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas E-M, Armstrong A, Im S-A, Song C-G, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Seok Lee L, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer Jr CE, Tutt ANJ	J CLIN ONCOL	42.1

Cancer	Trial	Title	Authors	Journal	Impact factor
Developmental Therapeutics	SAKK 65/16	TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)	Colombo I, Koster K, Holer L, Haeffliger S, Rabaglio M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin AM, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Jörger M	EUR J CANCER	8.4
	SAKK 65/16	Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I dose escalation trial (SAKK 65/16)	Mc Laughlin AM, Hess D, Michelet R, Colombo I, Haeffliger S, Bastian S, Rabaglio M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörger M, Kloft C	CANCER CHEMO PHARMACOL	2.7
	SAKK 80/19_ AlpineTIR	Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA study	Mark M, Mora AR, Winder T, Stathis A, Jakob A, Müller G, Hayoz S, Reimann P, Petrausch U, von Moos R	BONE REP	4.3
Gastrointestinal Cancers	PRODIGE 32	Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial	Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardiére C, Boilève A, Delaye M, Gourgou S, Pezzella V, Borg C	ANN ONCOL	56.7
	SAKK 41/16	Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: a multicenter phase Ib trial (RECAP)–SAKK 41/16	Bastian S, Jörger M, Holer L, Bärtschi D, Guckenberger M, Jochum W, Koeberle D, Siebenhüner AR, Wicki A, Berger MD, Winterhalder RC, Largiadèr CR, Löffler M, Mosna-Firlejczyk K, Maranta AF, Pestalozzi BC, Csajka C, von Moos R	CLIN COLORECTAL CANC	3.3
	SAKK 40/00	Is surgical quality more important than radicality? Long-term outcomes of stage I–III colon cancer (SAKK 40/00)	Maurer CA, Dietrich D, Schilling MK, Brauchli P, Kessler K, Käser SA	SURG ONCOL	2.3
Gynecological Cancers	ENGOT-en7_AtTEnd	Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial	Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP	LANCET ONCOL	41.6
Imaging in Diagnostic and Therapy Monitoring (IDaTM)		Advancements in lung cancer: a comprehensive perspective on diagnosis, staging, therapy and follow-up from the SAKK Working Group on Imaging in Diagnosis and Therapy Monitoring	Jungblut L, Rizzo SM, Ebner L, Kobe A, Nguyen-Kim TDL, Martini K, Roos J, Puligheddu C, Afshar-Oromieh A, Christe A, Dorn P, Funke-Chambour M, Hötter A, Frauenfelder T	SWISS MED WKLY	4.2

Cancer	Trial	Title	Authors	Journal	Impact factor
Leukemias	CLL13	First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial	Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B	LANCET ONCOL	41.6
	GRAALL 2003, GRAALL 2005	NGS-based stratification refines the risk stratification in T-ALL and identifies a Very High-Risk subgroup of patients	Simonin M, Vasseur L, Lengliné E, Lhermitte L, Cabannes-Hamy A, Balsat M, Schmidt A, Dourthe ME, Touzart A, Graux C, Gardel N, Cayuela JM, Arnoux I, Gandemer V, Rigal-Huguet F, Ducassou S, Lheritier V, Chalandon Y, Ifrah N, Dombret H, Macintyre EA, Petit A, Rousselot P, Lambert J, Baruchel A, Boissel N, Asnafi V	BLOOD	20.3
	GRAAPH-2014	Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia	Chalandon Y, Rousselot P, Chevreton S, Cayuela JM, Kim R, Huguet F, Chevallier P, Graux C, Thiebaut-Bertrand A, Chantepie S, Thomas X, Vincent L, Berthon C, Hicheri Y, Raffoux E, Escoffre-Barbe M, Plantier I, Joris M, Turlure P, Pasquier F, Belhabri A, Roth Guepin A, Blum S, Gregor M, Lafage-Pochitaloff M, Quessada J, Lhéritier V, Clappier E, Boissel N, Dombret H	BLOOD	20.3
	GRAAPH-2014	Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study	Kim R, Chalandon Y, Rousselot P, Cayuela JM, Huguet F, Balsat M, Passet M, Chevallier P, Hicheri Y, Raffoux E, Leguay T, Chantepie S, Maury S, Hayette S, Solly F, Braun T, De Prijck B, Cacheux V, Salanoubat C, Farnault L, Guibaud I, Lamarque M, Gastaud L, Lemasle E, Brissot E, Tavernier E, Bilger K, Villate A, Soulier J, Graux C, Lhéritier V, Dombret H, Boissel N, Clappier E	J CLIN ONCOL	42.1
	HOVON 102	High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML)	Bajrami Saipi M, Ruiba A, Schittenhelm MM, Blumenstock G, Gyorffy B, Fazio S, Hafner M, Ahrens AL, Aldinger L, Aellig V, Kavelaars FG, Nombela-Arrieta C, Fend F, Valk PJM, Christoph D, Kampha-Schittenhelm KM	CELL DEATH DIS	8.1

Cancer	Trial	Title	Authors	Journal	Impact factor
Leukemias	HOVON 132	Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial	van der Maas NG, Versluis J, Nasserinejad K, van Rosmalen J, Pabst T, Maertens J, Breems D, Manz M, Cloos J, Ossenkoppele GJ, Floisand Y, Gradowska P, Löwenberg B, Huls G, Postmus D, Pignatti F, Cornelissen JJ	BLOOD CANCER J	12.9
	NCRI-AML18, HOVON-SAKK, HO81, HO103, HO102, HO132	Risk Stratification in Older Intensively Treated Patients With AML	Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, Kennedy A, Moore R, Boertjes E, Vonk CM, Kavelaars FG, Rijken M, Gilkes A, Schwab C, Beverloo HB, Manz M, Visser O, Van Elssen CHMJ, de Weerd O, Tick LW, Biemond BJ, Vekemans MC, Freeman SD, Harrison CJ, Cook JA, Dennis M, Knapper S, Thomas I, Craddock C, Ossenkoppele GJ, Löwenberg B, Russell N, Valk PJM, Vyas P	J CLIN ONCOL	42.1
Lung Cancers	ETOP BOOSTER	ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial	Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Proven- cio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA	CLIN CANCER RES	10.4
	SAKK 19/17	First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17	Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi R, Fi- scher Maranta A, Bastian S, von Moos R, Jörger M, Früh M	EUR J CANCER	7.6
	SAKK Services	First-line chemo-immunotherapy in SCLC: outcomes of a binational real-world study	Moliner L, Zellweger N, Schmid S, Bertschinger M, Waibel C, Cerciello F, Froesch P, Mark M, Bettini A, Häuptle P, Blum V, Holer L, Hayoz S, Früh M	J THORAC ONCOL CLIN RES REP	3
Lymphomas	HD 21	Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage, classical Hodgkin lymphoma	Evens AM	LANCET	98.4
	HOVON 127/ SAKK 37/16	Effectiveness of fractionated rituximab in preventing tumorlysis syndrome in aggressive B-cell lymphoma: Insights fromreal-life clinical practice	Mohamad J, Bouroumeau A, McKee TA, Mach N, Samii K, Chamuleau M, Stenner F, Tamburini J, Lang N	CANCER REP	1.5

Cancer	Trial	Title	Authors	Journal	Impact factor
Lymphomas	TRIANGLE	Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network	Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevli K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E	LANCET	98.4
	SAKK 38/07	Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma	Ferrández MC, Golla SSV, Eertink JJ, Wiegers SE, Zwezerijnen GJC, Heymans MW, Lugtenburg PJ, Kurch L, Hüttmann A, Hanoun C, Dührsen U, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Zijlstra JM, Boellaard R; PETRA Consortium	J NUCL MED	9.1
Melanomas	SAKK Services	Effects of CTLA-4 Single Nucleotide Polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanoma	de Joode K, Rojas Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard CL, Läubli H, Michielin H, von Moos R, Jörgen M, Levesque MP, Aeppli S, Mangana J, Mangas C, Meyer S, Leoni-Parvex S, Mathijssen R, Metaxas Y	JIT	3.9
Network for Outcomes Research		Cost-Effectiveness & Budget Impact Analysis of Olaparib for BRCA 1/2 Germline-mutated Pancreatic Cancer	Mehra T, Lupatsch JE, Kössler T, Dedes K, Siebenhüner AR, von Moos R, Wicki A, Schwenkglenks ME	PLOS ONE	2.9
Radio-Oncology	SAKK Services	Deep inspirational breast hold (DIBH) for right breast irradiation: Improved sparing of liver and lung tissue	Mader T, Pace R, Boucas da Silva RT, Erwin Johannes Adam L, Näf G, Charles Winter C, Maria Aspradakis M, Radovic M, Spyridonidis A, Hayoz S, Gertrud Baumert B	CLIN TRANSL RADIAT ONCOL	2.7

Cancer	Trial	Title	Authors	Journal	Impact factor
Urogenital Cancers	SAKK 09/10	Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography-guided Salvage Radiotherapy Following Prostatectomy	Zamboglou C, Staus P, Wolkewitz M, Peeken JC, Ferentinos K, Strouthos I, Farolfi A, Koerber SA, Vrachimis A, Spohn SKB, Aebersold DM, Grosu AL, Kroeze SGC, Fanti S, Hruby G, Wiegel T, Emmett L, Hayoz S, Ceci F, Guckenberger M, Belka C, Schmidt-Hegemann NS, Ghadjar P, Shelan M	EUR UROL FOCUS	9.6
	SAKK 06/17	Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine	Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Özdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Müntener M, Bubendorf L, Schneider M, Musilova J, Petrausch U, Cathomas R	BJU INT	3.7
	SAKK 09/10	Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial	Zwahlen DR, Schröder C, Holer L, Bernhard J, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Martin Putora P, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Giovanni Bosetti D, Reuter C, Gomez S, Khanfir K, Beck M, Thalmann GN, Aebersold DM, Ghadjar P	CLIN TRANSL RADIAT ONCOL	3.1
	SAKK Services	Efficacy and tolerability of Bacillus Calmette-Guérin Strain Russia for the treatment of non-muscle-invasive bladder cancer – analysis of a prospective registry	Flury-Sutter S, Heuzeroth F, Arbelaez E, Bubendorf L, Püschel H, Hayoz S, Rentsch CA	CAN UROL ASSOC J	1.9
	SAKK Services	Metronomic Cyclophosphamide for Bone Marrow Carcinomatosis in Metastatic Castration-resistant Prostate Cancer	Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt C	J CANCER RES CLIN ONCOL	2.7
	SAKK Services	Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING)	Wetterauer C, Matthias M, Püschel H, Deckart A, Bubendorf L, Mortezaei A, Arbelaez E, Jean Winkel D, Heye T, Boll DT, Merkle E, Hayoz S, Seifert HH, Rentsch CA	EUR UROL FOCUS	4.9
Other		The active involvement of patients in oncology research	Ganz-Blaettler U, Liptrott SJ, Tolotti A, Cefali M, Aeschlimann C, Vilei SB, Colombo I, Hatzia Andreou E, Kosmidis T, Linardou H, Pfau R, Sgourou S, Sessa C	CANCER TREAT REV	9.6
SAKK services		Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single centre study with inpatient comparison	Johnson K, Stoffel B, Schwitler M, Hayoz S, Rojas Mora A, Fischer A, El Saadany T, Hasler U, von Moos R, Patzen A, Mark M, Roberts G, Cathomas R	SUPPORT CARE CANCER	2.8